The five-year disease-specific survival amongst gastric cancer patients with a high TLR5 expression was 53.4% (95% CI 43.4–63.4), compared to 37.6% (95% CI 30.0–45.2) among those with a low TLR5 expression (p = 0.014; Table 5 and Fig. 2D). Here, TLR5 is linked to gastric cancer.